Evidence map›Paper›PMID 33984044›Full record

Observational studyPloS one2021

How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda-A qualitative study.

Jonathan Ross, Charles Ingabire, Francine Umwiza, Josephine Gasana, Athanase Munyaneza, Gad Murenzi, Sabin Nsanzimana, Eric Remera, Matthew J Akiyama, Kathryn M Anastos and 1 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Jonathan RossDivision of General Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.ORCID 0000-0001-6126-3048
Charles IngabireClinical Education and Research Division, Rwanda Military Hospital, Kigali, Rwanda.ORCID 0000-0002-6700-6410
Francine UmwizaClinical Education and Research Division, Rwanda Military Hospital, Kigali, Rwanda.
Josephine GasanaClinical Education and Research Division, Rwanda Military Hospital, Kigali, Rwanda.
Athanase MunyanezaClinical Education and Research Division, Rwanda Military Hospital, Kigali, Rwanda.
Gad MurenziClinical Education and Research Division, Rwanda Military Hospital, Kigali, Rwanda.
Sabin NsanzimanaInstitute for HIV Disease Prevention and Control, Rwanda Biomedical Center, Kigali, Rwanda.
Eric RemeraInstitute for HIV Disease Prevention and Control, Rwanda Biomedical Center, Kigali, Rwanda.
Matthew J AkiyamaDivision of General Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Kathryn M AnastosDivision of General Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Adebola AdedimejiDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Rwanda Military Hospital · RWAlbert Einstein College of Medicine · USRwanda Biomedical Center · RW

Funding

"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Joan Weinberger Berman · 2017 to 2026
$28.3M
Minimizing losses from HIV care under universal treatment in RwandaK23MH114752 · NIMH · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ROSS, JONATHAN · 2017 to 2021
$995k
NIAID NIH HHS P30 AI124414NIAID NIH HHS U01 AI096299NIMH NIH HHS K23 MH114752
6 · The paper itself

Abstract

introductionHIV treatment guidelines recommend that all people living with HIV (PLWH) initiate antiretroviral therapy (ART) as soon as possible after diagnosis (Treat All). As Treat All is more widely implemented, an increasing proportion of PLWH are likely to initiate ART when they are asymptomatic, and they may view the relative benefits and risks of ART differently than those initiating at more advanced disease stages. To date, patient perspectives of initiating care under Treat All in sub-Saharan Africa have not been well described.

methodsFrom September 2018 to March 2019, we conducted individual, semi-structured, qualitative interviews with 37 patients receiving HIV care in two health centers in Kigali, Rwanda. Data were analyzed using a mixed deductive and inductive thematic analysis approach to describe perceived barriers to, facilitators of and acceptability of initiating and adhering to ART rapidly under Treat All.

resultsOf 37 participants, 27 were women and the median age was 31 years. Participants described feeling traumatized and overwhelmed by their HIV diagnosis, resulting in difficulty accepting their HIV status. Most were prescribed ART soon after diagnosis, yet fear of lifelong medication and severe side effects in the immediate period after initiating ART led to challenges adhering to therapy. Moreover, because many PLWH initiated ART while healthy, taking medications and attending appointments were visible signals of HIV status and highly stigmatizing. Nonetheless, many participants expressed enthusiasm for Treat All as a program that improved health as well as health equity.

conclusionFor newly-diagnosed PLWH in Rwanda, initiating ART rapidly under Treat All presents logistical and emotional challenges despite the perceived benefits. Our findings suggest that optimizing early engagement in HIV care under Treat All requires early and ongoing intervention to reduce trauma and stigma, and promote both individual and community benefits of ART.

Indexed as

Social StigmaAdultAnti-HIV AgentsFemaleFocus GroupsHealth Knowledge, Attitudes, PracticeHIV InfectionsHumansLongitudinal StudiesMalePatient Acceptance of Health CarePractice Guidelines as TopicQualitative ResearchRwandaTime-to-TreatmentYoung AdultAnti-HIV Agents

Identifiers

PMID33984044
PMCPMC8118273
OpenAlexW3161876077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.